Prevalence of <i>EGFR</i> mutations in patients with resected stage I-III non-small cell lung cancer: results from EARLY-EGFR Latin America study.

ABSTRACT:

Background

Although targeted and immune-based therapies are now recommended for early-stage non-small cell lung cancer (NSCLC), data on biomarker prevalence in Latin America (LATAM) remain limited. The aim of the descriptive, observational, real-world, EARLY-EGFR (NCT04742192) study was to determine the frequency of EGFR-mutated (EGFRm) in patients with resected stage I-III NSCLC across Asia, Middle East and Africa and LATAM.

Methods

The LATAM subset prospectively enrolled patients with surgically resected stage IA-IIIB [American Joint Committee on Cancer (AJCC) 8th edition] non-squamous NSCLC from March 2021 to October 2022. Primary endpoint was EGFRm prevalence and secondary endpoints were EGFRm subtypes, clinico-demographics and treatment patte

SUBMITTER: Kajatt EA 

PROVIDER: S-EPMC12780410 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature